Human Stem Cells Institute

ISKJ

RU000A0JNAB6

Healthcare Facilities & Services

End-of-day quote Moscow Micex - RTS Other stock markets 03:30:00 08/07/2022 am IST			5-day change	1st Jan Change
59.54 ^RUB	+1.43%		-.--%	-.--%

26/04	Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Human Stem Cells Institute PAO Announces Dividend

August 06, 2019 at 07:35 pm IST

Human Stem Cells Institute PAO announced to pay RUB 17,868,139.52 in dividends, RUB 14.08 per common stock for the year 2018.

Latest news about Human Stem Cells Institute

Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023	27/04	CI
Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
GENETICO PJSC has completed an IPO in the amount of RUB 178.8 million.	25/23/25	CI
GENETICO PJSC has filed an IPO.	21/22/21	CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Half Year Ended June 30, 2022	31/22/31	CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 611.63608 million in funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy	19/22/19	CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Full Year Ended December 31, 2021	05/22/05	CI
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company acquired 6.93% stake in Public Joint-Stock Company "Human Stem Cells Institute".	15/22/15	CI
GENETICO LLC announced that it expects to receive RUB 228.948921 million in funding from Public Joint-Stock Company "Human Stem Cells Institute"	27/21/27	CI
Public Joint-Stock Company Human Stem Cells Institute Reports Earnings Results for the Half Year Ended June 30, 2021	31/21/31	CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it expects to receive funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy	19/21/19	CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 400 million in funding from Limited Liability Company "IceGen 2"	23/21/23	CI
Public Joint-Stock Company Human Stem Cells Institute Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received funding from Limited Liability Company "IceGen 2"	08/21/08	CI
Public Joint-Stock Company "Human Stem Cells Institute" and Artur Isaev acquired 17.79% interest in GENETICO LLC from RVC Biopharmaceutical Investments, Limited liability Company, managed by RVC, Investment Arm.	26/20/26	CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it expects to receive funding from Limited Liability Company "IceGen 2"	23/20/23	CI
An unknown buyer acquired 15% stake in Human Stem Cells Institute PJSC from Mezhdunarodnogo Meditsinskogo Centra Obrabotki i Kriokhraneniya Biomaterialy.	13/19/13	CI
Human Stem Cells Institute PAO Announces Dividend	06/19/06	CI
Artur Isayev acquired 16.68% stake in Human Stem Cells Institute PJSC.	22/18/22	CI
An unknown buyer acquired 16.68% stake in Human Stem Cells Institute PJSC from Artur Isayev.	22/18/22	CI
MirMam OOO acquired 16.68% stake in Human Stem Cells Institute PJSC.	22/18/22	CI
Human Stem Cells Institute PJSC Announces Reviewed Consolidated Interim Results for the First Nine Months of 2017	27/17/27	CI
The Human Stem Cells Institute Announces Unaudited Consolidated Revenue Results for the First Quarter of 2017	19/17/19	CI
Human Stem Cells Institute PJSC Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	09/17/09	CI

Chart Human Stem Cells Institute

Duration

Period

More charts

Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HUMAN STEM CELLS INSTITUTE	-.--%	50.29M
HCA HEALTHCARE, INC.	+17.73%	83.47B
CVS HEALTH CORPORATION	-32.08%	69.72B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-3.24%	26.37B
FRESENIUS SE & CO. KGAA	+4.13%	17.86B
LABCORP HOLDINGS INC.	-13.68%	16.83B
QUEST DIAGNOSTICS INCORPORATED	+0.75%	15.7B
NATERA, INC.	+74.92%	13.45B
TENET HEALTHCARE CORPORATION	+73.16%	12.81B
REDE D'OR SÃO LUIZ S.A.	-2.02%	12.44B